# Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

Source: https://onco.cc/trials/nct07336732/  
OnCo record `nct07336732` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of PLB1004 in non-small-cell lung cancer, run by Avistone Biotechnology Co., Ltd., now recruiting.

## Summary

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations is a phase 2 interventional study registered as NCT07336732 by Avistone Biotechnology Co., Ltd., with 40 participants planned, started 2026-03-11 and due to reach its primary completion in 2026-11. Interventions recorded: PLB1004.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07336732
- Phase: 2
- Setting: An Open-label, Randomized, Multicenter Phase II/III Study to Evaluate the Efficacy and Safety of Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harboring Atypical EGFR Mutations Who Have Not Received Prior Systematic Therapy
- Sponsor: Avistone Biotechnology Co., Ltd.
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT07336732: https://clinicaltrials.gov/study/NCT07336732

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Avistone Biotechnology](https://onco.cc/companies/avistone-biotechnology/)

---
JSON: https://onco.cc/api/v1/entities/nct07336732.json